Amundi’s Prelude Therapeutics PRLD Stock Holding History

Amundi’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,130	Closed	-$52K	–	2026
2024 Q1	$52K	Hold	15,130	–	–	﹤0.01%	1840
2023 Q4	$61.4K	Buy	+15,130	New	+$46.1K	﹤0.01%	1859

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Amundi's PRLD Position: Q2 2024 in Review

Amundi sold out of Prelude Therapeutics (PRLD) in Q2 2024, closing a stake of 15,130 shares — an estimated $52K sold.

Amundi first reported a position in PRLD in Q4 2023 and held it in 2 quarters. The position peaked at $61.4K in Q4 2023. 61 funds tracked by Wall St. Rank hold PRLD as of Q2 2024.

Amundi reported no remaining Prelude Therapeutics position as of Q2 2024 after selling out during the quarter.
Amundi sold 15,130 Prelude Therapeutics shares in Q2 2024, an estimated $52K.
Amundi first reported a position in Prelude Therapeutics in Q4 2023 and held it in 2 quarters.
Amundi's Prelude Therapeutics position peaked at $61.4K in Q4 2023.
61 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2024.

Based on Amundi's 13F filing for Q2 2024, filed 14 Aug 2024.